The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Bladder Cancer
Open accessAbstract
Urothelial tumors represent a spectrum of diseases with a range of prognosis. After a diagnosis is established at any point within the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location and at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, because most recurrences are superficial and can be managed endoscopically. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development with the goal of optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches, using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. Although these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. Experts believe, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 5,997
Sylvester, R. J., van der Meijden, A. P. M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W. W., & Kurth, K. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.031 · Cited by 3,013
Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., White, R. W. D., Sarosdy, M. F., Wood, D. P., Raghavan, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022148 · Cited by 2,668
Self-citationvon der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
SYLVESTER, R. J., van der MEIJDEN, A. P. M., & LAMM, D. L. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64273-5 · Cited by 1,312
EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E., Böhle, A., Palou-Redorta, J., & Rouprêt, M. (2011) · European Urology · doi:10.1016/j.eururo.2011.03.017 · Cited by 1,067
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., Sreenivasan, T., Hendron, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106106 · Cited by 962
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), T. E. O. F. R. A. T. O. C. G.-U. T. C. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3139 · Cited by 949
SYLVESTER, R. J., OOSTERLINCK, W., & van der MEIJDEN, A. P. M. (2004) · Journal of Urology · doi:10.1097/01.ju.0000125486.92260.b2 · Cited by 743
Malmström, P.-U., Sylvester, R. J., Crawford, D. E., Friedrich, M., Krege, S., Rintala, E., Solsona, E., Di Stasi, S. M., & Witjes, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.04.038 · Cited by 662
Sternberg, C. N., de Mulder, P. H. M., Schornagel, J. H., Théodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, F., Spina, M., van Groeningen, C. J., de Balincourt, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2638 · Cited by 628
BÖHLE, A., JOCHAM, D., & BOCK, P. R. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)64043-8 · Cited by 616
Sternberg, C. N., de Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, J. A., Spina, M., van Groeningen, C. J., Duclos, B., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.032 · Cited by 542
Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., Boehle, A., Chevreau, C., Paz-Ares, L., Laufman, L. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6979 · Cited by 526
Skinner, D. G., Daniels, J. R., Russell, C. A., Lieskovsky, G., Boyd, S. D., Nichols, P., Kern, W., Sakamoto, J., Krailo, M., & Groshen, S. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)38368-4 · Cited by 524
Shipley, W. U., Winter, K., Kaufman, D. S., Lee, W. R., Heney, N. M., Tester, W., Donnelly, B. J., Venner, P. M., Perez, C. A., Murray, K. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3576 · Cited by 496
Self-citationCoppin, C., Gospodarowicz, M. K., James, K. W., Tannock, I. F., Zee, B. C.-Y., Carson, J., Pater, J. L., & Sullivan, L. D. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2901 · Cited by 472
Böhle, A., & Bock, P. R. (2004) · Urology · doi:10.1016/j.urology.2003.11.049 · Cited by 465
Leissner, J., Hohenfellner, R., Thüroff, J. W., & Wolf, H. K. (2000) · BJU International · doi:10.1046/j.1464-410x.2000.00614.x · Cited by 444
Efstathiou, J. A., Spiegel, D. Y., Shipley, W. U., Heney, N. M., Kaufman, D. S., Niemierko, A., Coen, J. J., Skowronski, R. Y., Paly, J. J., McGovern, F. J., et al. (2012) · European Urology · doi:10.1016/j.eururo.2011.11.010 · Cited by 435
Self-citationBladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
Lokeshwar, V. B., Habuchi, T., Grossman, H. B., Murphy, W. M., Hautmann, S. H., Hemstreet, G. P., Bono, A. V., Getzenberg, R. H., Goebell, P., Schmitz-Dräger, B. J., et al. (2005) · Urology · doi:10.1016/j.urology.2005.08.064 · Cited by 431
Gakis, G., Efstathiou, J., Lerner, S. P., Cookson, M. S., Keegan, K. A., Guru, K. A., Shipley, W. U., Heidenreich, A., Schoenberg, M. P., Sagaloswky, A. I., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.009 · Cited by 422
Self-citationSYLVESTER, R. J., van der MEIJDEN, A. P. M., WITJES, J. A., & KURTH, K. (2005) · Journal of Urology · doi:10.1097/01.ju.0000162059.64886.1c · Cited by 385
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
McCaffrey, J. A., Hilton, S., Mazumdar, M., Sadan, S., Kelly, W. K., Scher, H. I., & Bajorin, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1853 · Cited by 371
WINQUIST, E., KIRCHNER, T. S., SEGAL, R., CHIN, J., LUKKA, H., & on behalf of the GENITOURINARY CANCER DISEASE SITE GROUP OF CANCER CARE ONTARIO PROGRAM IN EVIDENCE-BASED CARE PRACTICE GUIDELINES INITIATIVE (2004) · Journal of Urology · doi:10.1097/01.ju.0000090967.08622.33 · Cited by 358
Shelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D. (2004) · BJU International · doi:10.1111/j.1464-410x.2003.04655.x · Cited by 342
Han, R. F., & Pan, J. G. (2006) · Urology · doi:10.1016/j.urology.2005.12.014 · Cited by 340
Shelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., & Mason, M. D. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02306.x · Cited by 313
Lorusso, V, Pollera, C. F., Antimi, M., Luporini, G., Gridelli, C., Frassineti, G. L., Oliva, C., Pacini, M., & De Lena, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00030-6 · Cited by 286
The 2004 WHO Classification of Bladder Tumors: A Summary and Commentary
Montironi, R., & Lopez-Beltran, A. (2005) · International Journal of Surgical Pathology · doi:10.1177/106689690501300203 · Cited by 278
Millikan, R., Dinney, C., Swanson, D., Sweeney, P., Ro, J. Y., Smith, T. L., Williams, D., & Logothetis, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4005 · Cited by 271
Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer
Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.937 · Cited by 269
Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay
Grossman, H. B. (2006) · JAMA · doi:10.1001/jama.295.3.299 · Cited by 265
Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
Kaufman, D., Raghavan, D., Carducci, M., Levine, E. G., Murphy, B., Aisner, J., Kuzel, T., Nicol, S., Oh, W., & Stadler, W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1921 · Cited by 257
Self-citationDi̇vri̇k, R. T., Yildirim, Ü., Zorlu, F., & Özen, H. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)01002-5 · Cited by 250
Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium
Sweeney, C. J., Roth, B. J., Kabbinavar, F. F., Vaughn, D. J., Arning, M., Curiel, R. E., Obasaju, C. K., Wang, Y., Nicol, S. J., & Kaufman, D. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6699 · Cited by 244
Efstathiou, J. A., Bae, K., Shipley, W. U., Kaufman, D. S., Hagan, M. P., Heney, N. M., & Sandler, H. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5776 · Cited by 222
Self-citationCognetti, F., Ruggeri, E. M., Felici, A., Gallucci, M., Muto, G., Pollera, C. F., Massidda, B., Rubagotti, A., Giannarelli, D., Boccardo, F., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr354 · Cited by 222
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.
Herr, H. W., Bajorin, D. F., & Scher, H. I. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1298 · Cited by 203
Self-citationFedeli, U., Fedewa, S. A., & Ward, E. M. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.09.015 · Cited by 187
Gudjónsson, S., Adell, L., Merdasa, F., Olsson, R., Larsson, B., Davidsson, T., Richthoff, J., Hagberg, G., Grabe, M., Bendahl, P. O., et al. (2009) · European Urology · doi:10.1016/j.eururo.2009.01.006 · Cited by 182
Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer
Raj, G. V., Herr, H., Serio, A. M., Donat, S. M., Bochner, B. H., Vickers, A. J., & Dalbagni, G. (2007) · Journal of Urology · doi:10.1016/j.juro.2006.11.090 · Cited by 180
Self-citationUrinary Bladder Cancer: Role of MR Imaging
Verma, S., Rajesh, A., Prasad, S. R., Gaitonde, K., Lall, C. G., Mouraviev, V., Aeron, G., Bracken, R. B., & Sandrasegaran, K. (2012) · RadioGraphics · doi:10.1148/rg.322115125 · Cited by 178
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00370-8 · Cited by 169
De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Skoneczna, I., Marreaud, S., de Wit, R., & Sylvester, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4924 · Cited by 169
Huncharek, M. S., McGarry, R. C., & Kupelnick, B. (2001) · PubMed · Cited by 131
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
Galsky, M. D., Mironov, S., Iasonos, A. E., Scattergood, J., Boyle, M. G., & Bajorin, D. F. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9020-9 · Cited by 125
Papamichael, D., Gallagher, C., Oliver, R. T. D., Johnson, P., & Waxman, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.106 · Cited by 118
Berrum-Svennung, I., Granfors, T., Jahnson, S., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.166 · Cited by 92
Cited by
Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., Guo, C. C., Lotan, Y., & Kassouf, W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30512-8 · Cited by 1,421
Mak, R. H., Hunt, D., Shipley, W. U., Efstathiou, J. A., Tester, W. J., Hagan, M. P., Kaufman, D. S., Heney, N. M., & Zietman, A. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5548 · Cited by 465
Self-citationPetrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., Vavassori, I., & Barni, S. (2014) · European Urology · doi:10.1016/j.eururo.2013.06.049 · Cited by 331
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Faltas, B. M., Prandi, D., Tagawa, S. T., Molina, A. M., Nanus, D. M., Sternberg, C., Rosenberg, J., Mosquera, J. M., Robinson, B., Elemento, O., et al. (2016) · Nature Genetics · doi:10.1038/ng.3692 · Cited by 294
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B., Lamm, D., O'Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 252
Metadata
- Authors
- Clark, P. E., Agarwal, N., Biagioli, M. C., Eisenberger, M. A., Greenberg, R. E., Herr, H. W., Inman, B. A., Kuban, D. A., Kuzel, T. M., Lele, S. M., Michalski, J., Pagliaro, L. C., Pal, S. K., Patterson, A., Plimack, E. R., Pohar, K. S., Porter, M. P., Richie, J. P., Sexton, W. J., Shipley, W. U., Small, E. J., Spiess, P. E., Trump, D. L., Wile, G., Wilson, T. G., Dwyer, M., & Ho, M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2013-04
- Volume
- 11
- Issue
- 4
- Pages
- 446-475
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W169084277
- Cited by
- 317
- References
- 50
- FWCI
- 42.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.